Post by Fredy Comanescu

Every once in a while, a biotech delivers data that changes the whole conversation. On September 24th, uniQure (QURE) did just that. Their gene therapy for Huntington’s disease, AMT-130, slowed disease progression by 75% at three years in the high-dose group. Patients didn’t just see numbers improve — they experienced it in daily life: better function, better biomarkers, and outcomes that simply hadn’t been seen before in this devastating condition. I’ve been following and invested in this company for three years, and while the road hasn’t always been easy, this moment feels like a turning point. Management’s discipline, the smart design of new cohorts, upcoming FDA and EU milestones, and even early signs from other programs like epilepsy suggest that this could just be the beginning of something historic. This is not only about stock prices or market caps. It’s about hope for families who have been waiting for decades. And with U.S. progress already in motion, EU regulators could soon unlock access for thousands more patients across the world. #innovation #biotech #genetherapy #HuntingtonsDisease #healthcare #patientcare #QURE #FDA #leadership #medicalbreakthrough